NCI Definition [1]:
An antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting human epidermal growth factor receptor 2 (EGFR2; HER2; ErbB2) and conjugated to an as of yet undisclosed cytotoxic agent, with potential antineoplastic activity. Upon administration of anti-HER2 ADC DP303c, the antibody moiety targets and binds to HER2 on tumor cells. Upon antibody/antigen binding and internalization, the cytotoxic agent induces tumor cell apoptosis, through an as of yet not publicly known mechanism. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.

Dp303c has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating dp303c, 1 is phase 1 (1 open).

ERBB2 Amplification, HER2 Overexpression, and HER2 Positive are the most frequent biomarker inclusion criteria for dp303c clinical trials.

Malignant solid tumor is the most common disease being investigated in dp303c clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Dp303c
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating dp303c and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,931 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-her2 antibody-drug conjugate dp303c, dp 303c, dp-303c
Drug Target(s) [2]:
NCIT ID [1]:


1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.